Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1Phase 3 1Phase 1 1

Status

Completed 51Terminated 7Unknown 5Active not recruiting 2Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 47Genitourinary 43Other hematologic neoplasm 12Plasma cell 7Myeloid 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 6Recurrence 2Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Terminated × Prednisone × Plasma cell × Clear all
NCT04083898 2024-03-19

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Washington University School of Medicine

Phase 1 Terminated
15 enrolled
Plasma cell

Multiple Myeloma

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02773550 2020-01-18

Velcadito

Basque Health Service

Phase 4 Terminated
24 enrolled
Plasma cell

Multiple Myeloma

NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT01116128 2011-06-14

D-MP

Fondazione EMN Italy Onlus

Phase 2 Terminated
8 enrolled
Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT00644306 2008-03-26

IFM 01/01

Central Hospital, Nancy, France

Phase 3 Terminated
232 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡